1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | PL21 |
| Species | Human |
| Cat.No | ABL-TC0554 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Peripheral Blood |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Leukemia Cell Lines |
PL-21 is a human acute promyelocytic leukemia (APL) cell line, classified under FAB M3 subtype, it was derived from the peripheral blood of a 24-year-old male patient. Unlike typical APL lines, PL-21 lacks the classic APL-associated t(15;17) translocation, making it a distinctive model for studying non-canonical APL pathways. PL-21 cells grow in single-cell suspension, display features of immature nuclei and prominent cytoplasmic azurophilic granules. They exhibit monocytic differentiation profile, confirmed by the strong expression of surface markers CD14/CD68 and the presence of monocyte-specific esterase. PL-21 lacks lymphoid characteristics and is EBNA-negative. Its capacity makes it particularly valuable for investigating non-canonical APL pathways.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
PL-21 cell line serves as a unique and versatile model in leukemia research, particularly for exploring non-classical APL mechanisms. It provides excellent platform for studying myeloid cell proliferation and differentiation mechanisms. Additionally, researchers have employed PL-21 cells to investigate the roles of key oncogenic drivers such as p53, FLT3, and KRAS, offering critical insights into their involvement in leukemogenesis and therapeutic resistance. Due to its distinct genetic and phenotypic profile, PL-21 is highly suitable for drug screening, molecular pathway analysis, and the development of targeted treatments for atypical forms of AML and APL.
